Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441301 | 1.00 | TSHR (0.60) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL14559833 | 0.88 | L3MBTL1 (0.51) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL137925 | 0.87 | YWHAG (0.50) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL1558288 | 0.87 | CA2 (0.60) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL13742793 | 0.85 | MAPT (0.48) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL90470 | 0.85 | CYP3A4 (0.49) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL18524140 | 0.85 | MAPT (0.48) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL7266886 | 0.85 | ALDH1A1 (0.49) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| SCHEMBL3227920 | 0.84 | POLB (0.49) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL90469 | 0.84 | MAPT (0.50) | TSHRSMN1; SMN2ALOX15HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-109836524-B | Catalyst composition, ethylene-alpha-olefin polymer and preparation method thereof | 中国石油天然气股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210161863-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | MCKINNEY ANTHONY ALEXANDER (US) | 2021-06-03 | — | — | US | disclosed |
| CN-105960402-B | Microbicidal heterobicyclic derivatives | 先正达参股股份有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-109836524-A | Catalyst composition, ethylene- α -olefin polymer and preparation method thereof | 中国石油天然气股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109836523-A | Catalyst composition, ethylene- α -olefin polymer and preparation method thereof | 中国石油天然气股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20180256542-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2018-09-13 | — | — | US | disclosed |
| CN-107954999-A | Han oxadiazole rings compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2018-04-24 | — | — | CN | disclosed |
| US-20160346249-A1 | USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2016-12-01 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| US-5965576-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| US-5705505-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1998-01-06 | — | — | US | disclosed |
| US-5589489-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1996-12-31 | — | — | US | disclosed |
| EP-0734383-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161863-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | TSHR 1370/4885SMN1; SMN2 2457/4885ALOX15 992/4885 |
| US-20160346249-A1 | USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | CYP2D6, MAOB, HTR1A | TSHR 2280/4885SMN1; SMN2 1539/4885ALOX15 337/4885 |
| US-20180256542-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | TSHR 1370/4885SMN1; SMN2 2457/4885ALOX15 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.